The Gut Microbiome in Obesity and Diabetes: Emerging Links and Modulation Strategies

Bwanbale Geoffrey David

Faculty of Pharmacy Kampala International University Uganda

                                                                                   ABSTRACT
The intestinal microbiome is a dense, metabolically active ecosystem that shapes host energy balance, immunity,
and endocrine signaling. In obesity and type 2 diabetes (T2D), characteristic alterations reduced microbial
diversity, depletion of fiber-fermenting taxa, expansion of mucus-degraders and pathobionts, and shifts in the
virome/mycobiome associated with insulin resistance (IR) and glycemic dysregulation. Mechanistically,
dysbiosis modifies production of short-chain fatty acids (SCFAs), bile-acid (BA) pools, and tryptophan-derived
indoles; increases branched-chain amino acids and imidazole propionate; perturbs intestinal barrier integrity;
and primes innate immunity via endotoxin (LPS) and other microbe-associated molecular patterns. These
changes alter gut–brain and gut–liver axes, decrease GLP-1/peptide YY signaling, promote hepatic steatosis,
and impair skeletal-muscle insulin signaling. Interventions that restore eubiosis, dietary fiber and polyphenols,
Mediterranean/plant-forward patterns, time-restricted feeding, physical activity, and sleep regularity
consistently improve metabolic endpoints. Clinical trials of pre-, pro-, and synbiotics show modest but
reproducible benefits on IR and inflammatory markers; fecal microbiota transplantation (FMT) yields transient
improvements in insulin sensitivity in selected recipients but lacks durable efficacy without diet/lifestyle
co-intervention. Emerging strategies include defined microbial consortia, engineered commensals,
bacteriophages, and targeted postbiotics (e.g., SCFA donors, secondary BA modulators). Precision microbiome
medicine combining metagenomics, metatranscriptomics, metabolomics, and host genomics/immune profiling
may identify responder endotypes and guide individualized therapy. This review synthesizes current evidence
linking the gut ecosystem to obesity/T2D pathophysiology, maps metabolite and immune pathways to clinical
phenotypes, and evaluates modulation strategies across lifestyle, nutritional, and microbial therapeutics,
emphasizing pragmatic translation and safety.

Keywords: gut microbiome; insulin resistance; short-chain fatty acids; bile acids; fecal microbiota
transplantation.

CITE AS: Bwanbale Geoffrey David. (2026). The Gut Microbiome in Obesity and Diabetes: Emerging Links and Modulation Strategies. Research Output Journal of Biological and Applied Science 6(1):27-35. https://doi.org/10.59298/ROJBAS/2026/612735